
Andrew Robbins, Cogent Biosciences CEO
Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial
Cogent Biosciences said it’s working on an FDA submission for its systemic mastocytosis (SM) drug after breezing through a Phase 2 trial in an indolent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.